Quest Partners LLC Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Quest Partners LLC reduced its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 34.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,418 shares of the company’s stock after selling 1,794 shares during the period. Quest Partners LLC’s holdings in Kymera Therapeutics were worth $162,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after purchasing an additional 769,486 shares during the last quarter. American International Group Inc. boosted its stake in shares of Kymera Therapeutics by 6.4% in the first quarter. American International Group Inc. now owns 20,095 shares of the company’s stock valued at $808,000 after purchasing an additional 1,209 shares during the period. California State Teachers Retirement System boosted its stake in shares of Kymera Therapeutics by 5.5% in the first quarter. California State Teachers Retirement System now owns 40,423 shares of the company’s stock valued at $1,625,000 after purchasing an additional 2,102 shares during the period. Comerica Bank grew its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after purchasing an additional 400 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Kymera Therapeutics during the 1st quarter worth approximately $207,000.

Kymera Therapeutics Stock Up 1.9 %

Shares of NASDAQ KYMR opened at $46.86 on Friday. The business has a 50-day moving average price of $46.88 and a 200 day moving average price of $42.11. The stock has a market cap of $3.03 billion, a PE ratio of -20.03 and a beta of 2.21. Kymera Therapeutics, Inc. has a 52-week low of $19.11 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the company earned ($0.90) earnings per share. The company’s revenue was down 20.9% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on KYMR shares. Morgan Stanley boosted their price target on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 price target on the stock. UBS Group lowered their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Finally, Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $52.13.

Insiders Place Their Bets

In other news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.